FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL									
	OMB Number: 3235-0									
l	Estimated average burden									
l	hours per response:	0.5								

	Check this box if no longer subject
	to Section 16. Form 4 or Form 5
\Box	obligations may continue. See
	Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

				0, 000		0(11) 0	· uic i		inchie C	Julipariy Act	01 10-1								
Name and Address of Reporting Person* Divis Gregory J					2. Issuer Name and Ticker or Trading Symbol AVADEL PHARMACEUTICALS PLC								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Divis Gregory J					AVDL 1								X Dire		or 10%		10% O	wner	
(Last) (First) (Middle)												-	X	Office belov	er (give title v)		Other (: below)	specify	
C/O AVADEL PHARMACEUTICALS PLC					3. Date of Earliest Transaction (Month/Day/Year) 08/10/2023								Chief Executive Officer						
10 EARLSFORT TERRACE				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applic Line)					Applicable		
													X Form filed by One Reporting Person					son	
' '	(Street) DUBLIN 2 L2 D02 T380												Form filed by More than One Reporti Person						
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication														
					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea				2A. Deemed Execution Da if any (Month/Day/Y		Date,	ate, Trai		ransaction Dispos			ed (A) or tr. 3, 4 and	and 5) Secu Bene Owne Follo		icially d ving		Direct ct (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						c		ode	v .	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)					
ADSs ⁽¹⁾ 08/10/2023					3			P		10,000	A	\$13.199	1997(2)		159,100		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (I 8)		5. Numl of Deriv Secu Acqu (A) oi Dispo of (D) (Instr	rative rities ired r osed)	Expi	iration I	e Exercisable and tion Date n/Day/Year)		le and unt of urities erlying rative rity r. 3 and 4)	Deri	rice of vative urity tr. 5)	ative derivative ity Securities	Ow For Dire or I (I) (0. Dwnership Orm: Oirect (D) r Indirect) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(A) (D)		: rcisable	Expiration Date	Title	Amount or Number of Shares	1						

Explanation of Responses:

- 1. The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
- 2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$12.86 to \$13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

<u>/s/ Jerad G. Seurer, Attorney-in-Fact</u>

08/10/2023

Date

<u>In-Fact</u>

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.